Get the Daily Brief
Latest Biotech News
Single-cell genomics scale-up: 10x Genomics acquires Scale Biosciences
10x Genomics announced the acquisition of Scale Biosciences for $30 million upfront plus milestones, aiming to advance its Chromium single-cell platform through innovative combinatorial indexing...
Advancements in pediatric cancer genomics and diagnostics
Boston Children’s Hospital, Dana-Farber Cancer Institute, and Broad Clinical Labs have launched BrightSeq, a collaborative clinical research consortium providing integrated tissue and liquid...
Novel protein evolution platform accelerates therapeutic discovery
Researchers at Scripps Research have developed T7-ORACLE, a synthetic biology platform capable of accelerating protein evolution by thousands of times natural rates. This 'evolution engine'...
Advances and challenges in cancer immunotherapy and targeted therapies
Recent developments highlight progress in cancer immunotherapy, including Genmab and AbbVie’s Epkinly demonstrating positive Phase 3 results for follicular lymphoma, potentially enabling earlier...
Biotech financing and strategic industry shifts amid market volatility
Despite a biotech funding environment marked by declines and uncertainty, several companies have successfully raised capital to fuel innovation. Frazier Life Sciences secured $1.3 billion in its...
Innovations in neurodegenerative disease research and therapies
Groundbreaking research reveals lithium deficiency in human and mouse brains as a contributing factor to the onset and progression of Alzheimer’s disease. Amyloid plaque binding reduces lithium...
Pediatric radiology and imaging innovations improve diagnostics
Recent pediatric radiological studies have advanced knowledge across diverse conditions. Innovations include MRI-guided hydrostatic reduction for intussusception, reduced sedation techniques with...
HHS cancels $500 million mRNA vaccine R&D contracts amid policy shift
The U.S. Department of Health and Human Services (HHS) announced termination of 22 Biomedical Advanced Research and Development Authority (BARDA) contracts totaling nearly $500 million dedicated...
Strand Therapeutics raises $153 million for programmable mRNA cancer therapies
Strand Therapeutics, an MIT spinout developing programmable mRNA-based immunotherapies for solid tumors, secured $153 million in a Series B fundraising round led by prominent investors including...
Eli Lilly’s oral GLP-1 obesity pill delivers modest weight loss in Phase 3 data
Eli Lilly disclosed Phase 3 results for orforglipron, an oral small molecule GLP-1 receptor agonist for obesity, showing a 12.4% mean weight loss over 72 weeks at the highest dose, falling short...
Adaptive Biotechnologies posts 36% revenue growth fueled by minimal residual disease testing
Adaptive Biotechnologies reported Q2 2025 revenues of $58.9 million, marking a 36% increase year over year, mainly driven by robust demand for its clinical and pharmaceutical minimal residual...
10x Genomics acquires Scale Biosciences to enhance single-cell biology platform
10x Genomics announced a definitive agreement to acquire single-cell biology company Scale Biosciences for $30 million upfront plus milestone-based contingent payments. Scale’s technologies,...
Merck’s $10 billion acquisition of Verona Pharma reveals no competing bids
Merck finalized a $10 billion acquisition of Verona Pharma, the maker of the newly FDA-approved COPD drug ensifentrine, amidst an atypical absence of competing offers. Documentation revealed Merck...
FDA grants accelerated approval to Jazz Pharmaceuticals’ Modeyso for rare brain cancer
The FDA granted accelerated approval to dordaviprone (Modeyso), developed by Jazz Pharmaceuticals following its acquisition of Chimerix, as the first systemic therapy for recurrent H3 K27M-mutant...
Bio-Techne reports 4% fiscal Q4 revenue growth amid macroeconomic uncertainty
Bio-Techne announced fiscal Q4 2025 revenues of $317 million, a 4% year-over-year increase, driven by strong performance in protein sciences and cell therapy workflow consumables despite a slight...
Scientists reveal lithium deficiency’s role in Alzheimer’s pathology and reversal strategy
Harvard Medical School researchers identified brain lithium deficiency as an early and pivotal factor in Alzheimer’s disease onset and progression. Through mouse models and human tissue studies,...
Frazier Life Sciences Raises $1.3 Billion for Early-Stage Biopharma
Frazier Life Sciences closed its twelfth venture fund, FLS XII, securing $1.3 billion in capital commitments to invest in company creation and early-stage private biopharmaceutical firms. Since...
US Health Agencies Cancel $500M in mRNA Vaccine Funding
The US Department of Health and Human Services (HHS) announced the cancellation of nearly $500 million in contracts for 22 mRNA vaccine development projects under the Biomedical Advanced Research...
Strand Therapeutics Raises $153 Million to Advance Programmable mRNA Cancer Drugs
Strand Therapeutics has secured $153 million in a Series B financing round led by global investors including Kinnevik, Regeneron Ventures, Amgen Ventures, and Eli Lilly. The funding will support...
Eli Lilly’s Oral GLP-1 Obesity Drug Shows Modest Weight Loss Benefits
Eli Lilly disclosed results from a pivotal Phase 3 trial of its oral GLP-1 receptor agonist, orforglipron, reporting an average placebo-adjusted weight loss of 11.2% over 72 weeks in adults with...